亚虹医药：APL-1401用于治疗中重度活动性溃疡性结肠炎的Ⅰb期临床试验获积极初步结果

Core Insights - Aihong Pharmaceutical (688176) announced positive preliminary results from its Phase Ib clinical trial of APL-1401 for the treatment of moderate to severe active ulcerative colitis [1] - Based on these positive results, the company plans to further evaluate the potential first-in-class therapy in a larger population of moderate to severe active ulcerative colitis patients over a 12-week treatment period [1] - The aim is to provide more comprehensive supportive evidence for subsequent clinical research, with the goal of offering new treatment options for patients in the future [1]